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Objectives To determine if detection of IgM and IgG antibodies against mycobacterial
antigen A60, together with the Mantoux tuberculin skin test (TST), could be used in the
diagnosis of tuberculous pleurisy (TP) in BCG-vaccinated cases.
Methods We investigated 125 BCG-vaccinated patients with pleural effusion. Of these,
88 had TP and 37 had non-tuberculous pleurisy (NTP). TST and anti-A60 IgM and IgG
measurements by ELISA were performed in the sera and pleural effusions of both
groups.
Results Cut-off values, in optical density, for serum anti-A60 IgM, pleural ﬂuid anti-A60
IgM, serum anti-A60 IgG and pleural ﬂuid anti-A60 IgG were deﬁned as 0.624, 0.614,
0.464, and 0.613, respectively. TP patients had higher IgG and IgM levels in the serum
(P< 0.001 and P< 0.05, respectively) and pleural effusion (P< 0.001 and P< 0.001,
respectively). Regardless of the diagnosis, IgG and IgM levels were higher in the sera
(P< 0.001 and P< 0.05, respectively) and pleural effusions (P< 0.001 and P< 0.001,
respectively) of TST-positive cases, and serum and pleural ﬂuid IgM levels were higher
(P< 0.001 and P< 0.001, respectively) in the TST-positive TP cases. Sensitivity and
speciﬁcity of TST were 65% and 68%, respectively. As a single parameter, pleural ﬂuid
anti-A60 IgM had the highest sensitivity (77%) and speciﬁcity (94%) in patients with
negative TST.
Conclusion We suggest that in populations where tuberculosis prevalence is high and
BCG vaccination is common, pleural ﬂuid anti-A60 IgM can facilitate the diagnosis of TP.
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INTRODUCTION
Tuberculosis (TB) continues to be a major health
problem, especially in developing countries. Per-
sons suspected of having TB should be referred for
a medical evaluation, which should include med-
ical history, physical examination, Mantoux tuber-
culin skin test (TST), chest radiograph, and any
appropriate bacteriologic or histologic examina-
tions. In the case of extrapulmonary or pleural
TB, establishing a deﬁnite diagnosis is sometimes
a problem, even with the use of newer tests that
usemolecular, chromatographic and immunologic
methods. Tuberculous pleural effusion is esti-
mated to constitute approximately 5–30% of all
diseases due to Mycobacterium tuberculosis [1,2].
The primary diagnostic tests in tuberculous pleur-
itis involve sampling of the pleural ﬂuid and
pleural tissue. Pleural ﬂuid culture is positive
for M. tuberculosis in approximately 42% of
patients, while pleural biopsy culture is positive
in 64% [3]. TST with the use of puriﬁed protein
derivative (PPD) is the standard method of iden-
tifying persons infected withM. tuberculosis, and it
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is even more valuable in cases of tuberculous
pleurisy (TP), where diagnostic yields of routine
tests are much more limited when compared with
pulmonary TB. However, skin testing with PPD
gives rise to conﬂicting results in BCG (bacille
Calmette–Guerin)-vaccinated patients. BCG vacci-
nation is not generally recommended in the USA
and most other developed countries, whereas it is
a mandatory healthcare measure in much of the
world, where TB is still a scourge. The prevalence
of TB in Turkey is 0.35%, and 30 000–40 000 new
cases are reported every year [4]. In our experi-
ence, among patients referred to our hospital, the
proportion of TP among cases of pulmonary TB is
24% (unpublished data). In Turkey, until the year
1998, BCG vaccinations were performed routinely
on four occasions—soon after birth and at the ages
of 7, 12 and between 16 and 18 years, in the case of
a negative TST. This procedure has now been
changed; the ﬁrst vaccination is given in the sec-
ond month of life, and the second vaccination at
the age of 6–7 years. No other vaccination is
performed if two BCG scars exist due to vaccina-
tion, regardless of PPD status.
Several serologic methods, along with routine
tests, have been proposed for the diagnosis of
pulmonary TB. Among them, antigen A60 detec-
tion is one of the most studied tests. However, the
usefulness of A60-based serologic tests in BCG-
vaccinated cases has been less extensively evalu-
ated. The aim of this study was to investigate
whether detection of IgM and IgG antibodies
against mycobacterial antigen A60 in the serum
and pleural ﬂuid, together with TST, would be
helpful in the differential diagnosis of previously
BCG-vaccinated pleurisy cases.
MATERIALS AND METHODS
In a referral hospital for patients with TB, over a
9-month period, we investigated 125 BCG-vacci-
nated patients with tuberculous or non-tubercu-
lous pleural effusion, between the ages of 16 and
81 years (mean 31.68 19.18). Of these, 111 (89%)
were male and 14 (11%) were female. TP cases
consisted of 88 cases with an age range of 16–23
years (mean 21.05 0.87). Non-tuberculous
pleurisy (NTP) cases included 37 patients with
the diagnoses of pleuropulmonary malignancies
(22 cases), transudative effusions (seven), and
parapneumonic effusions (eight), with an age
range of 21–81 years (mean 57.81 16.40). Diag-
nosis of TP was made by the combined use of
histopathologic and bacteriologic examinations,
i.e. the demonstration of tubercle bacilli in the
sputum, pleural ﬂuid or pleural biopsy specimen,
or observation of caseous granulomas in the
pleura. Each patient had at least one positive
culture from sputum or pleural biopsy or pleural
ﬂuid. Previous BCG vaccination was conﬁrmed
via medical history records and observation of
BCG scars. The Mantoux skin test, with intracuta-
neous injection of 0.1mL of 5 tuberculin units of
PPD, was performed on each patient at once, and
the size of induration was measured after the 48th
hour but no later than the 72nd hour. A tuberculin
reaction of 10mm of induration was classiﬁed as
positive. Patients with factors that may cause false-
negative reactions to the TST (HIV positivity,
immunosuppressive state, live-virus vaccination,
overwhelming TB disease, etc.) were not included
in the study. With informed consent, a sample of
10mL of pleural ﬂuid was drawn and a pleural
biopsy taken from each subject under local
anesthesia by means of an Abrams needle. Five
milliliters of sample ﬂuid was sent for bacteriolo-
gic, biochemical and cytologic testing, and the
remaining 5mL was kept in a dry container (test
tube). To prevent clotting, 0.5mL of heparin was
added to each tube, and the tubes were kept at
20 8C until the time of ELISA serologic testing.
Pleural biopsy specimens were also sent for bac-
teriologic and histopathologic examination. For
microbiological examination, pleural biopsy speci-
mens were grounded in sterile 0.9% saline and
then inoculated concurrently in Lowenstein–Jen-
sen and Bactec 12B media. Sputum samples were
digested and decontaminated by the N-acetyl-L-
cysteine–sodium hydroxide method, and then
concentrated by centrifugation at 3000g for
15min. Pleural ﬂuid samples were concentrated
in the same way. Pleural ﬂuid and sputum sedi-
ments were also inoculated on Lowenstein–Jensen
and Bactec 12B media. Inoculated media were
incubated at 37 8C for 6weeks for Bactec 12B
and 8weeks for Lowenstein–Jensen. Lowen-
stein–Jensen medium was incubated for an addi-
tional 4weeks if a smear of inoculated material
was positive and the culture was negative at
8weeks. Culture results in Bactec 12B medium
were evaluated with appropriate equipment
(Bactec 460, Becton Dickinson, Sparks, Maryland,
USA). Smears of sputum, pleural biopsy and
pleural ﬂuid were stained with Ziehl–Neelsen
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and evaluated microscopically. Anti-A60 IgM and
anti-A60 IgG measurements by ELISA were per-
formed on the sera and pleural effusions of both
TP andNTP cases. Since we did not detect changes
over time in serum/pleural ﬂuid IgG and IgM
levels, we used only initial ﬁndings for all para-
meters, including TST. For statistical and clinical
evaluation purposes, all 125 cases were classiﬁed
into four groups according to the PPD skin test
results and ﬁnal diagnoses. The ﬁrst group com-
prised TP patients with a positive PPD skin test;
the second group comprised TP patients with a
negative PPD skin test; the third group comprised
NTP cases with a positive PPD skin test; and the
last group comprised NTP cases with a negative
PPD skin test, which was taken as the control
group in calculations of the cut-off values. No
patient had received antituberculous treatment.
ELISA for antibody-level determination
The diagnostic kits were obtained from Anda
Biologicals (Strasbourg, France). The A60 used
in these kits was prepared from the cytoplasm
ofMycobacterium bovis-BCG. Since BCG is virtually
antigenically equivalent to virulent strains of M.
tuberculosis, we considered A60 to be a reasonable
serologic marker in the diagnosis of TB. ELISA test
procedures for both IgG and IgM measurements
were performed as recommended by the manu-
facturer and described elsewhere [5,6]. The results
were interpreted by measuring the optical density
(OD) in the ELISA microtiter wells with a spectro-
photometer (ESR 200 ELISA Plate Reader;
Medispec, Palm City, FL, USA) at 450 nm. Mea-
surements were correlated with control curves
established from subjects with a negative standard
serum and from three positive standard sera at 1, 2
and 16 ELISA units. The absorbance value of 1
ELISA unit was 0.25 0.05, that of 2 ELISA units
was 0.50 0.05, and that of 16 ELISA units was
1.5 0.5. Results were considered positive if the
OD value was above the mean level plus 2 stan-
dard deviations (SD) measured in the control
group (non-tuberculous patients with a negative
TST).
Data analysis
We evaluated the diagnostic value of IgG and IgM
detection in the sera and pleural effusions of both
TP and NTP cases in terms of the sensitivity,
speciﬁcity, negative predictive value, positive pre-
dictive value, and overall accuracy. We also eval-
uated the accuracy and usefulness of the use of
these serologic tests in various combinations with
each other and/or with TST. These statistical tests
are formulated according to standards, and the
results can be calculated easily [7]. To calculate
these parameters, one must be given a cut-off
point, which is generally deﬁned as the mean
2 SD measured in a control population. We cal-
culated the cut-off values in the same way.
For comparison of mean titers, we ﬁrst per-
formed an analysis of variance, and then used
the t-test to compare one group to another, and
Pearson correlation analysis to look for the bivari-
ate correlation between pleural and serum levels
of the individual cases.
RESULTS
The contributions to diagnosis of the methods, in
this selected group of patients with a deﬁnite
diagnosis, were as follows. Positive cultures were
obtained from pleural biopsy in 71 (80%), pleural
ﬂuid in eight (9%) and sputum in 20 (22%) of the
cases. The other contributing ﬁndings were as
follows: observation of pleural granulomas in 80
(90%), smear positivity (pleural biopsy, pleural
ﬂuid, sputum) in 35 (39%) and lymphocyte pre-
dominance in pleural ﬂuid in 83 (94%) of the cases.
Table 1 shows the mean IgG and IgM levels,
given as OD values, in the sera and pleural effu-
sions of the TP and NTP cases. Both IgG and IgM




pleurisy n¼ 3 P-value
Serum IgM 0.704 0.487 0.306 0.212 P< 0.001
Pleural fluid IgM 1.060 0.488 0.321 0.192 P< 0.001
Serum IgG 0.372 0.378 0.252 0.165 P< 0.05
Pleural fluid IgG 0.633 0.416 0.384 0.250 P< 0.001
Table 1 IgG and IgM levels in the
serum and pleural fluid (given in
OD units)
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pleural effusions of TP cases. As a whole, when
taken as paired samples, pleural and serum levels
of IgM were signiﬁcantly correlated (r¼ 0.727,
P< 0.01). There was also a good correlation
between pleural and serum IgM levels in TP
patients (r¼ 0.694, P< 0.01), but aweak correlation
in NTP cases (r¼ 0.336, P< 0.05). The correlation
of pleural IgG with serum IgG was not strong as a
whole (all cases together), and in TP cases
(r¼ 0.440, P< 0.01, and r¼ 0.447, P< 0.01, respec-
tively), and there was no correlation in NTP cases
(r¼ 0.144, P¼ 0.395). When cases were classiﬁed
according to the PPD skin test results, regardless of
the diagnosis, IgG and IgM levels were higher in
the sera and pleural effusions of PPD-positive
cases (Table 2). Furthermore, when we classiﬁed
the cases into four groups according to the diag-
noses and skin test results, we found that, in the TP
group, PPD-positive cases had higher IgM OD
values in the serum and pleural ﬂuid (Table 3).
Pleural ﬂuid IgG levels were also higher in PPD-
positive TP cases. In the NTP group, pleural ﬂuid
IgG levels were signiﬁcantly higher in PPD-posi-
tive cases than in PPD-negative ones. These
results, in general, were in accordance with the
ﬁndings shown in Tables 1 and 2. It is noteworthy
that PPD skin test positivity rates (from Tables 2
and 3) were: 55% (69 patients) when all 125 cases
were taken together, 65% (57 patients) in TP
patients, and 32% (12 patients) in the NTP group.
Figures 1 and 2 show the IgM and IgG measure-
ments and mean values in the serum and pleural
ﬂuid of the four groups. Cut-off values in OD,
established in NTP patients with a negative PPD
skin test, were deﬁned as 0.624, 0.614, 0.464, and
0.613, respectively, for serum IgM, pleural ﬂuid
IgM, serum IgG, and pleural ﬂuid IgG. Thereafter,
we evaluated the sensitivity, speciﬁcity, positive
predictive value, negative predictive value and
overall accuracy of the use of these tests in various
combinations with each other and/or with TST
(Table 4).
DISCUSSION
Patients with TP almost invariably have a small
subpleural nidus of TB, even if there is no radi-
ologically apparent parenchymal disease, showing
ﬁbrous and granulomatous inﬂammation and
clear signs of leakage into the pleural space [8].
TP is an acute granulomatous pleurisy caused by
recent infection by the mycobacterium, thought to
result from a delayed hypersensitivity reaction to
mycobacterial antigens in the pleural space [9].
Table 2 IgG and IgM levels in the
serum and pleural fluid of PPD-po-






Serum IgM 0.793 0.511 0.330 0.188 P< 0.001
Pleural fluid IgM 1.053 0.551 0.581 0.400 P< 0.001
Serum IgG 0.391 0.358 0.270 0.290 P< 0.05
Pleural fluid IgG 0.679 0.396 0.412 0.331 P< 0.001













Serum IgM 0.896 0.488 0.350 0.210 P< 0.001 0.307 0.303 0.306 0.159 NS
Pleural fluid IgM 1.195 0.488 0.813 0.387 P< 0.001 0.375 0.245 0.294 0.160 NS
Serum IgG 0.406 0.381 0.309 0.372 NS 0.319 0.223 0.220 0.122 NS
Pleural fluid IgG 0.699 0.414 0.511 0.396 P¼ 0.042 0.582 0.288 0.289 0.162 P< 0.005
NS, not significant.
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These antigens probably enter the pleural space
after rupture of a subpleural focus of disease.
Sometimes, even the most sophisticated meth-
ods are not sufﬁcient to allow the correct diagnosis
to be made and treatment to be started on time.
The Mantoux test is still the standard for detecting
exposure to M. tuberculosis. The Centers for Dis-
ease Control and Prevention (CDC) suggests that a
tuberculin reaction of 10mm of induration be
classiﬁed as positive in persons living in high-
prevalence countries, or who are residents and
employees in high-risk settings [10]. Since Turkey
has a high prevalence of TB, and most of our TP
cases were army members, we considered an
induration of 10mm as positive.
The Mantoux test has a number of drawbacks,
including the need for a return visit, cross-reactiv-
ity with other mycobacterial species, the booster
effect, and false-negative results because of inter-
current immunosuppression, as well as the varia-
bility inherent in its application and reading [11].
Also, we are aware of some immunocompetent
cases in which, in spite of proven active TB, the
TST remains repeatedly negative [12]. On the other
hand, BCG vaccination is another important pro-
blem. The sensitivity of the Mantoux test in
patients with culture-positive TB has been esti-
mated to be 87%, with a speciﬁcity of 80% in a
non-vaccinated population [11]. In our BCG-vac-
cinated study group, sensitivity and speciﬁcity
rates for the PPD skin test were found to be 65%
and 68%, respectively. In another data analysis of
254 bacteriologically and/or pathologically pro-
ven TP patients, the frequency of PPD-positive
cases was only 66.5%, which is very close to our
result of 65% [13]. Distinguishing BCG infection
from TB may be difﬁcult, and the tuberculin test is
only one element in the assessment. Therefore, a
need for better testing methods has emerged.
Chiang et al. evaluated the efﬁcacy of different
mycobacterial-speciﬁc antigens and the combina-
tion of several different antigens in the diagnosis of
tuberculosis in 594 Chinese patients, and showed
that, among the three ELISA tests based on A60,
38 kDa and Kp90, A60 was better from the point of
view of sensitivity and speciﬁcity [14].
Figure 1 IgM levels, given in
OD units, in the serum and
pleural ﬂuid specimens: circles,
serum IgM; triangles, pleural
ﬂuid IgM; bars, mean IgM.
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Figure 2 IgG levels, given in OD
units, in the serum and pleural fluid
specimens: circles, serum IgG; trian-
gles, pleural fluid IgG; bars, mean
IgG.
Table 4 Accuracy and usefulness studies (given as %) of the serologic tests and PPD skin test in various combinations







PPD 65 68 83 28 70
Serum IgG 26 86 82 36 44
Serum IgM 48 92 93 39 61
Serum IgG or PPD 71 65 83 27 70
Serum IgM or PPD 66 62 80 26 65
Serum IgG and PPD 18 89 80 37 39
Serum IgM and PPD 45 97 97 41 61
Serum IgM or serum IgG 59 81 88 34 66
Serum IgM and serum IgG 15 97 93 41 39
Serum IgG or pleural IgG 53 76 84 32 60
Serum IgG and pleural IgG 15 89 76 37 36
Serum IgM or pleural IgM 79 89 94 37 82
Serum IgM and pleural IgM 45 97 97 41 61
Pleural IgG 42 76 80 32 52
Pleural IgM 77 94 97 40 82
Pleural IgG or PPD 73 65 83 27 70
Pleural IgM or PPD 87 65 85 27 81
Pleural IgG and PPD 34 78 79 33 47
Pleural IgM and PPD 54 100 100 42 68
Pleural IgM or pleural IgG 84 73 88 31 81
Pleural IgM and pleural IgG 34 97 97 41 53
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There are relatively few reports concerning the
relationship between TST and BCG vaccination
and/or serologic tests. A study from Poland,
involving 104 subjects without a history of TB
and 109 active pulmonary TB patients, reported
that there was no correlation between A60 ELISA
results and tuberculin reaction status, and the
serologic test could differentiate subjects with
non-active tuberculous infection from active dis-
ease better than the tuberculin test [15]. In several
studies, it has been reported that the anti-A60 IgG
test has good sensitivity (60–73%) and speciﬁcity
(75–96%) [16–18]. Mahajan et al. studied IgM anti-
bodies against A60 antigen by ELISA in TB
patients, and found a sensitivity of 77.5% and a
speciﬁcity of 87.5% [19]. Other workers investi-
gated the diagnostic value of the serum IgM levels
against A60 antigen in extrapulmonary and smear-
negative pulmonary TB, and the results indicated
a sensitivity of 10.5% and a speciﬁcity of 99.4% for
IgM [17]. A recent study from Turkey, using A60
by ELISA in the sera of active smear- and/or
culture-positive lung TB cases, demonstrated that
the sensitivity and speciﬁcity values were 53.6%
and 94.7% for IgG, and 43.8% and 97.4% for IgM
[20]. Thus, results from different sources show
great variations, depending on the population
studied and the site of the disease.
We found that when the diagnosis of TP is
deﬁnite and/or the PPD skin test is positive,
IgM and IgG levels are invariably higher in the
pleural ﬂuid than in serum (Tables 1–3). Also,
regardless of diagnosis, IgG and IgM levels were
higher in the sera and pleural effusions of PPD-
positive cases compared with the PPD-negative
group (Table 2). This may imply a relationship
between PPD positivity and humoral response
to TB infection and/or BCG vaccination, which
in turn supports the idea of the combined use of a
PPD skin test and serologic tests in problematic
cases. We also found that, in the TP group, pleural
ﬂuid IgG levels, but not serum IgG levels, were
signiﬁcantly higher in PPD-positive cases
(Table 3). Meanwhile, the pleural ﬂuid mean IgG
level, in contrast to serum IgG, was higher in PPD
responders in the NTP group. On this point, there
are conﬂicting data in the literature. Van Vooren
et al [21] reported that, in TP patients, the propor-
tion of speciﬁc IgG antibodies was higher in
pleural effusion than in serum, due to local pro-
duction, whereas Levy et al [22] suggested that the
level of IgG in the pleural ﬂuid was related to
passive diffusion from serum. However, in view of
some earlier studies, our ﬁndings did not seem to
be contradictory. It has been reported that there
was an inverse relationship between serum IgG
levels and the time elapsed since prior disease in
TB [5,23]. Also, high levels of antibody against
PPD could be associated with non-tuberculous
diseases, such as thoracic tumors [24]. Another
striking ﬁnding shown in Table 3 is that, whereas
pleural ﬂuid and serum IgM levels were not
affected by TST status in the NTP group, both
parameters were signiﬁcantly higher in PPD
responders in the TP group. This observation
may also suggest a relationship between humoral
response and TST positivity in TP patients.
Combined use of the serologic tests and TST
with an ‘and’ relation, which means that both tests
are positive, and with an ‘or’ relation, which
means that one of the two tests is positive and
the other negative, is shown in Table 4. From this
table, it can be seen that in our group of BCG-
vaccinated cases, PPD skin test positivity alone
was not a good diagnostic indicator. The combina-
tion of pleural IgM level with TST with an ‘or’
relation had the highest sensitivity (87%) but rela-
tively low speciﬁcity (65%), positive predictive
value (85%), and negative predictive value
(27%). On the other hand, the combination of
pleural IgM and PPD skin test positivity with an
‘and’ relation had the highest speciﬁcity (100%),
positive predictive value (100%), and negative
predictive value (42%), but a low sensitivity
(54%). If we consider the overall accuracy rates,
the use of pleural IgM alone or combined with
serum IgM with an ‘or’ relation had the highest
accuracy (Table 4). In general, pleural ﬂuid IgM
was involved in all combinations with good diag-
nostic accuracy, and it was even more valuable in
patients with a negative TST (sensitivity, 77%;
speciﬁcity, 94%; positive predictive value, 97%;
negative predictive value, 40%; overall accuracy,
82%). We also evaluated the diagnostic yield of
triple combinations of serologic tests and TST, but
the results were not superior to those of simple
combinations. In fact, ‘or’ relations had the lowest
speciﬁcity (59–65%) and ‘and’ relations had the
lowest sensitivity (12–43%). Thus, triple combina-
tions were not included in Table 4.
All of our cases were BCG vaccinated, most of
them more than once, and, for the great majority,
the last vaccination was at least 5 years ago. It
has been shown that BCG vaccination induces a
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speciﬁc antibody response against the A60 antigen
fractions, that remote BCG vaccination has a major
inﬂuence on the tuberculin reaction, and that no
single criterion can accurately separate reactions
caused by true infection from those caused by BCG
vaccination [25,26]. In any case, the antibody res-
ponse to M. tuberculosis is not thought to reﬂect
antituberculosis cell-mediated immunity [27].
Furthermore, it may be non-speciﬁc because of
cross-reactivity with atypical mycobacterial pro-
teins. Also, there are some studies reporting that
the BCG vaccination status does not affect the rate
of false-positive results of A60-based serologic
tests among healthy volunteers [28,29]. This issue
deserves further investigation.
We believe that the role of community-acquired
latent M. tuberculosis infection or BCG vaccination
in the positive response to PPD is difﬁcult to deﬁne
in our particular group of patients. The lack of
accepted microbiological methods sensitive
enough to identify individuals with latent M.
tuberculosis infection prevents comparison of the
true sensitivity and speciﬁcity of the PPD skin test
and the serologic tests. In view of our ﬁndings, we
suggest that in populations where TB prevalence is
high and BCG vaccination is considered a common
healthcare measure, ELISA using the A60 antigen
together with the PPD skin test may facilitate the
diagnosis of TP as an adjunct to other methods.
Additionally, we think that pleural ﬂuid IgM de-
tection has more diagnostic value than the other
serologic parameters studied, especially in patients
with a negative TST.
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